70,409 results match your criteria Targeted Cancer Therapy


Targeted anticancer prodrug therapy using dextran mediated enzyme-antibody conjugate and β-cyclodextrin-curcumin inclusion complex.

Int J Biol Macromol 2020 May 29. Epub 2020 May 29.

Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 14115-154, Iran. Electronic address:

A targeted and controlled drug delivery system based on β-cyclodextrin (β-CD) for encapsulation and controlled release of hydrophobic drugs in the presence of maltogenic amylase (MAase), as a cyclodextrin-hydrolyzing enzyme, and trastuzumab antibody has been developed. In this study, the inclusion complex of curcumin (CUR), as a model anticancer compound, with β-CD was prepared and we constructed an antibody-enzyme bioconjugate (dextran mediated MAase-Trastuzumab bioconjugate) for controlled and targeted release of CUR at HER2 positive cancer cells (including SKBR3 and BT474). Immunocytochemistry analysis indicated that the MAase-Trastuzumab bioconjugate had significant binding affinities to HER2 positive cancer cells and demonstrated high enzyme activity to degrade β-CD in order to rapid release of CUR on targeted cell surface. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2020.05.225DOI Listing

Next-generation sequencing identifies novel single nucleotide polymorphisms in high-risk cutaneous squamous cell carcinoma: A pilot study.

Exp Dermatol 2020 Jun 1. Epub 2020 Jun 1.

Department of Dermatology, University of Nebraska Medical Center, Omaha, NE, USA.

Background: Cutaneous squamous cell carcinoma (SCC) causes 1 million cases in the United States annually. There are germline single nucleotide polymorphisms (SNPs) that result in an increased risk of SCC and altered response to therapy.

Premise: There may be biologically relevant SNPs not detected using traditional GWAS studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.14120DOI Listing

Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy.

Nano Lett 2020 Jun 1. Epub 2020 Jun 1.

As a hallmark of solid tumors, hypoxia promotes tumor growth, metastasis, and therapeutic resistance by regulating the expression of hypoxia-related genes. Hypoxia also represents a tumor-specific stimulus that has been exploited for the development of bioreductive prodrugs and advanced drug delivery systems. Cell division cycle 20 (CDC20) functions as an oncogene in tumorigenesis, and we demonstrated the significant upregulation of CDC20 mRNA in the tumor vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.nanolett.0c00757DOI Listing

Management of glioblastoma: State of the art and future directions.

CA Cancer J Clin 2020 Jun 1. Epub 2020 Jun 1.

The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA.

Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predominance in males, and incidence increases with age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21613DOI Listing

Cytomembrane-mimicking nanocarriers with a scaffold consisting of a CD44-targeted endogenous component for effective asparaginase supramolecule delivery.

Nanoscale 2020 Jun 1. Epub 2020 Jun 1.

Chongqing Research Center for Pharmaceutical Engineering, Chongqing Medical University, Chongqing 400016, China.

Highly effective and safe delivery of therapeutic enzymes is pivotal to the success of antitumor therapy. Herein, we report on a targeted enzyme delivery system based on cytomembrane-mimicking nanocarriers (CmN) and a supramolecular technique (SmT). Specifically, each CmN had a scaffold that mainly consisted of a CD44-targeted endogenous component conjugated with polyethylene glycol 2000 (HA-g-PEG) that self-assembled with α-cyclodextrin (ACD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/d0nr02588gDOI Listing

Advances in targeted therapy for acute myeloid leukemia.

Biomark Res 2020 20;8:17. Epub 2020 May 20.

4The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008 China.

Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment related mortality rate in the past few decades, long term overall survival has stagnated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00196-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238648PMC

Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism.

Oncotarget 2020 May 12;11(19):1777-1796. Epub 2020 May 12.

Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Previously, we reported apolipoprotein A-I (apoA-I), the major protein component of high-density lipoprotein (HDL), has potent anti-melanoma activity. We used DNA microarray and bioinformatics to interrogate gene expression profiles of tumors from apoA-I expressing (A-I Tg) versus apoA-I-null (A-I KO) animals to gain insights into mechanisms of apoA-I tumor protection. Differential expression analyses of 11 distinct tumors per group with > 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233810PMC

BRAF mutation and its inhibitors in sarcoma treatment.

Cancer Med 2020 May 31. Epub 2020 May 31.

Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin, P.R. China.

The mitogen-activated protein kinase (MAPK) signaling pathway plays a significant role in mediating cellular physiological activities, such as proliferation, differentiation, apoptosis, and senescence. This signaling pathway is composed of several major proto-oncogenes of RAS/RAF/MEK/ERK, among which the BRAF proto-oncogene, as one of the three members of the RAF family, has a higher mutation rate than ARAF and CRAF and has attracted extensive attention. Regarding the BRAF mutation, approximately 95% of BRAF mutations belong to the BRAF V600E mutation, which can enhance the expression of the MAPK signaling pathway and is thus related to the occurrence and development of various malignant tumors and has been successfully identified as a therapeutic target. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3103DOI Listing

Ag@S-nitrosothiol core-shell nanoparticles for chemo and photothermal synergistic tumor targeted therapy.

J Mater Chem B 2020 Jun 1. Epub 2020 Jun 1.

Key Laboratory of Functional Polymer Materials, Ministry of Education, Institute of Polymer Chemistry, Nankai University, Tianjin 300071, P. R. China.

Along with the development of controlled delivery systems for targeted therapy, 'single-strategy' therapy often fails to achieve the desired performance in real body internal environments. In such a case, it is necessary to develop synergistic therapy strategies. Herein, for the first time, we designed and synthesized hyaluronic acid (HA) modified Ag@S-nitrosothiol core-shell nanoparticles for synergistic tumor cell targeted therapy based on photothermal therapy (PTT) and nitric oxide (NO) based chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/d0tb00734jDOI Listing

Preliminary Evaluation of Astatine-211-Labeled Bombesin Derivatives for Targeted Alpha Therapy.

Chem Pharm Bull (Tokyo) 2020 ;68(6):538-545

Graduate School of Medical Sciences, Kanazawa University.

There are various diagnostic and therapeutic agents for prostate cancer using bombesin (BBN) derivatives, but astatine-211 (At)-labeled BBN derivatives have yet to be studied. This study presented a preliminary evaluation of At-labeled BBN derivative. Several nonradioactive iodine-introduced BBN derivatives (IB-BBNs) with different linkers were synthesized and their binding affinities measured. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/cpb.c20-00077DOI Listing
January 2020

Targeted delivery of honokiol by zein/hyaluronic acid core-shell nanoparticles to suppress breast cancer growth and metastasis.

Carbohydr Polym 2020 Jul 28;240:116325. Epub 2020 Apr 28.

Institute of Medicine and Drug Research, Qiqihar Medical University, Qiqihar, PR China. Electronic address:

Based on the antisolvent and electrostatic deposition methods, we fabricated zein/hyaluronic acid core-shell nanoparticles loaded with honokiol (HA-Zein-HNK), which could target delivery and enhance the therapeutic effect of the HNK. The prepared nanoparticles were found to have a mean size of 210.4 nm and negative surface charge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carbpol.2020.116325DOI Listing

Alginate-zinc (II) phthalocyanine conjugates: Synthesis, characterization and tumor-associated macrophages-targeted photodynamic therapy.

Carbohydr Polym 2020 Jul 11;240:116239. Epub 2020 Apr 11.

College of Chemistry, State Key Laboratory of Photocatalysis on Energy and Environment, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, Fuzhou University, Fuzhou 350108, China. Electronic address:

Tumor-associated macrophages (TAMs)-targeted photodynamic therapy (PDT) has dual-selectivity and hence is promising in cancer treatment. Since the scavenger receptor-A (SR-A) on TAMs can recognize polyanions, two molecular-weight sodium alginates (SA1, 41.2 kDa; SA2, 1231. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carbpol.2020.116239DOI Listing

Microbiome and cancer treatment: Are we ready to apply in clinics?

Authors:
Stephen L Chan

Prog Mol Biol Transl Sci 2020 29;171:301-308. Epub 2020 Apr 29.

State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; Hand in Hand Cancer Foundation Limited, Hong Kong Special Administrative Region, China. Electronic address:

Cancer treatment has been evolving in recent decades from surgery, conventional chemotherapy and radiation therapy to targeted therapies and more recently immunotherapies. Despite significant improvement in the efficacy of treatment with the discovery of novel therapies targeting particular cancer-related gene and proteins and more recently the immune system-modulating biologics, still only patients with specific subtypes of cancer benefit from those targeted therapies and there is room for further improvement of survival outcomes. As failure of cancer treatment is not uncommon in clinical practice, a lot of biomarker studies have been carried out with an aim to identify factors contributing to disease relapse and treatment failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.pmbts.2020.04.004DOI Listing

Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.

Target Oncol 2020 May 30. Epub 2020 May 30.

Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.

Background: γ-Glutamyltransferase (GGT) is a marker of oxidative stress. Elevated serum GGT is linked to poor survival in various malignancies; however, there are no data on metastatic renal cell carcinoma (mRCC). Additionally, GGT expression in cancer tissues remains largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-020-00719-9DOI Listing

Luteolin-loading of Her-2-poly (lactic-co-glycolic acid) nanoparticles and proliferative inhibition of gastric cancer cells via targeted regulation of forkhead box protein O1.

J Cancer Res Ther 2020 ;16(2):263-268

Digestive Department, Union Hospital of Fujian Medical University, Gulou, Fuzhou, Fujian, P.R. China.

Background: Developing the natural medicine that allow for the specific targeting cytotoxicity is a very important research area in the development of anti-tumor drugs.

Aims And Objectives: This study was conducted to determine the targeted inhibitory effects of luteolin-loaded Her-2-poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) on gastric cancer cells and to delineate the mechanism underlying the inhibition of tumors by luteolin.

Materials And Methods: Luteolin-loaded Her-2-PLGA NPs (Her-2-NPs) were prepared, physically and chemically characterized, and their effects on gastric cancer cells were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_438_18DOI Listing
January 2020

Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.

Crit Rev Oncol Hematol 2020 May 23;151:102992. Epub 2020 May 23.

Genitourinary Oncology Section, Dana Farber Cancer Institute, Boston, MA, USA.

Background: Both docetaxel and androgen-receptor-axis-targeted (ARAT) agents are approved in metastatic castration-sensitive prostate cancer (mCSPC) patients. Predictive factors of therapy efficacy are lacking.

Methods: We included articles reporting data about randomized-controlled clinical trials (RCTs) testing an ARAT agent plus ADT vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.102992DOI Listing

Targeted uptake of folic acid-functionalized polymeric nanoparticles loading glycoalkaloidic extract in vitro and in vivo assays.

Colloids Surf B Biointerfaces 2020 May 13;192:111106. Epub 2020 May 13.

School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address:

Solanum lycocarpum fruits contain two major glycoalkaloids (GAs), solamargine (SM) and solasonine (SS). These compounds are reported as cytotoxic. However, they have poor water solubility and low bioavailability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.colsurfb.2020.111106DOI Listing

Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.

Nucl Med Biol 2020 May 23;86-87:44-51. Epub 2020 May 23.

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd, Xiamen 361102, China. Electronic address:

Objective: Accurate evaluation of tumor programmed death ligand 1 (PD-L1) expression can assist in predicting whether a patient will respond to anti-PD-L1 therapy. In this study, we aimed to develop stable radioiodinated PD-L1 antibodies that can be used for PD-L1 targeted SPECT/PET imaging.

Methods: Radioiodination was accomplished via a prosthetic group ([I]SIB or [I]SIB) to give radioiodinated anti-human PD-L1 and anti-mouse PD-L1 antibody (anti-PD-L1 and anti-PD-L1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2020.05.006DOI Listing

The choice of anti-tumor strategies based on micromolecules or drug loading function of biomaterials.

Cancer Lett 2020 May 28. Epub 2020 May 28.

Department of Urology, The Second Hospital of TianJin Medical University, TianJin Institute of Urology, Tianjin, 300211, China. Electronic address:

With advances in modern medicine, diverse tumor therapies have been developed. However, because of a lack of effective methods, the delivery of drugs or micromolecules in the human body has many limitations. Biomaterials are natural or synthetic functional materials that are prone to contact or interact with living systems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2020.05.019DOI Listing

Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment.

Adv Drug Deliv Rev 2020 May 28. Epub 2020 May 28.

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States. Electronic address:

Various bioactive ingredients have been extracted from Chinese herbal medicines (CHMs) that affect tumor progression and metastasis. To further understand the mechanisms of CHMs in cancer therapy, this article summarizes the effects of five categories of CHMs and their active ingredients on tumor cells and the tumor microenvironment. Despite their treatment potential, the undesirable physicochemical properties (poor permeability, instability, high hydrophilicity or hydrophobicity, toxicity) and unwanted pharmacokinetic profiles (short half-life in blood and low bioavailability) restrict clinical studies of CHMs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.addr.2020.05.006DOI Listing

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.

Lancet 2020 May 28. Epub 2020 May 28.

Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, UK.

Background: Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)31173-9DOI Listing

LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression.

Mol Cancer 2020 May 30;19(1):98. Epub 2020 May 30.

Clinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, 529030, China.

Background: Anti-angiogenic therapy represents a promising strategy for non-small-cell lung cancer (NSCLC) but its application in lung squamous cell carcinoma (SQC) is limited due to the high-risk adverse effects. Accumulating evidence indicates that long noncoding RNAs (lncRNAs) mediate in tumor progression by participating in the regulation of VEGF in NSCLC, which might guide the development of new antiangiogenic strategies.

Methods: Differential lncRNA expression in SQC was analyzed in AE-meta and TCGA datasets, and further confirmed in lung cancer tissues and adjacent normal tissues with RT-qPCR and in-situ hybridization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-020-01217-2DOI Listing

A real-time cell-binding assay reveals dynamic features of STxB-Gb3 co-internalization and STxB-mediated cargo delivery into cancer cells.

FEBS Lett 2020 May 30. Epub 2020 May 30.

Ridgeview Instruments AB, Science Park, 75237, Uppsala, Sweden.

The interaction between the Shiga toxin B-subunit (STxB) and its globotriaosylceramide receptor (Gb3) has a high potential for being exploited for targeted cancer therapy. The primary goal of this study was to evaluate the capacity of STxB to carry small molecules and proteins as cargo into cells. For this purpose, an assay was designed to provide real-time information about the StxB-Gb3 interaction as well as the dynamics and mechanism of the internalization process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1873-3468.13847DOI Listing

Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review.

Cancer Treat Rev 2020 May 27;87:102032. Epub 2020 May 27.

University of Toronto, Toronto, ON, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Cutaneous melanoma is typically treated with wide local excision and, when appropriate, a sentinel node biopsy. Many patients are cured with this approach but for patients who have cancers with high risk features there is a significant risk of local and distant relapse and death. Interferon-based adjuvant therapy was recommended in the past but had modest results with significant toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102032DOI Listing

Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.

Pharmacol Res 2020 May 27:104932. Epub 2020 May 27.

State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China; Guangdong-Hong Kong-Macao Joint Laboratory for Smart Discrete Manufacturing, Guangzhou 510006, China. Electronic address:

Precision oncology involves effectively selecting drugs for cancer patients and planning an effective treatment regimen. However, for Molecular targeted drug, using genomic state of the drug target to select drugs has limitations. Many patients who could benefit from molecularly targeted drugs, but they are being missed due to the insufficient labelling ability of the existing target genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2020.104932DOI Listing

Goal-directed versus Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy: A Prospective Randomized Controlled Trial.

Anesthesiology 2020 May 26. Epub 2020 May 26.

From the Department of Anesthesiology and Critical Care Medicine, Anesthesiology Service, Memorial Sloan Kettering Cancer Center, New York, New York (V.A.-C., A.C.P., M.F.) the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (K.S.T.) the Department of Surgery, Urology Service, Weill Cornell Medical College, New York, New York. (G.D., H.W.H., B.H.B., E.K.C., T.F.D., S.M.D.) the Department of Urology, Weill Cornell Medical College, New York, New York. (G.D., H.W.H., B.H.B., E.K.C., S.M.D.) Departments of Anesthesiology, Weill Cornell Medical College, New York, New York. (A.C.P., M.F.).

Background: Postoperative ileus is a common complication of intraabdominal surgeries, including radical cystectomy with reported rates as high as 32%. Perioperative fluid administration has been associated with improvement in postoperative ileus rates, but it is difficult to generalize because earlier studies lacked standardized definitions of postoperative ileus and other relevant outcomes. The hypothesis was that targeted individualized perioperative fluid management would improve postoperative ileus in patients receiving radical cystectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ALN.0000000000003367DOI Listing

Breast cancer: are long-term and intermittent endocrine therapies equally effective?

J Cancer Res Clin Oncol 2020 May 29. Epub 2020 May 29.

Munich Cancer Registry (MCR), Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-University (LMU), 81377, Munich, Germany.

Purpose: In breast cancer (BC), the duration of endocrine adjuvant therapies (AT) has been extended continuously up to 10 years. We present an alternative explanation for the effect, which could enable shorter treatments.

Method: The relevant literature on chemoprevention and (neo-)adjuvant therapy was reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-020-03264-0DOI Listing

Near IR responsive targeted integrated lipid polymer nanoconstruct for enhanced magnolol cytotoxicity in breast cancer.

Sci Rep 2020 May 29;10(1):8771. Epub 2020 May 29.

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

Advances in cancer nanotechnology aim at improving specificity and effectiveness for tumor treatment. Amalgamation of different treatment modalities is expected to provide better cancer combating. Herein, We developed a long circulating nanocarrier comprising trastuzumab (TZB) surface modified polylactic-co-glycolic acid (PLGA) nanoparticles (NPs) co-encapsulating magnolol (Mag) and gold nanoparticles (GNPs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-65521-zDOI Listing

Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.

Proc Natl Acad Sci U S A 2020 May 29. Epub 2020 May 29.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239;

Acute myeloid leukemia (AML) is a deadly hematologic malignancy with poor prognosis, particularly in the elderly. Even among individuals with favorable-risk disease, approximately half will relapse with conventional therapy. In this clinical circumstance, the determinants of relapse are unclear, and there are no therapeutic interventions that can prevent recurrent disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1918307117DOI Listing

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.

Int J Mol Sci 2020 May 27;21(11). Epub 2020 May 27.

Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.

Introduction: Targeted agents such as bevacizumab (BEV) or poly (ADP-ribose) polymerase inhibitors (PARPi) which have been added as concomitant or maintenance therapies have been shown to improve progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PS rOC). In the absence of direct comparison, we performed a network meta-analysis considering genes status.

Methods: We searched PubMed, EMBASE, and MEDLINE for trials involving patients with PS rOC treated with BEV or PARPi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21113805DOI Listing

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Transl Oncol 2020 May 26;13(9):100795. Epub 2020 May 26.

Azienda Ospedaliera Careggi University Hospital of Florence and University of Florence, 50134 Florence, Italy.

BRAFV600-mutated colorectal cancer (CRC) accounts for 8% to 12% of all CRC diagnoses. These tumors are often associated with specific patient features, including right-sided primary tumor location, peritoneal and non-regional lymph node involvement, and poor prognosis. In approximately 30% of cases, a simultaneous mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) phenotype is identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2020.100795DOI Listing

Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.

Int J Cardiol 2020 May 26. Epub 2020 May 26.

Division of Cardiovascular Disease, UAB | The University of Alabama at Birmingham, Birmingham, AL 35294-1913, USA. Electronic address:

The advent of tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment of chronic myeloid leukemia (CML) patients. However, cardiotoxicity associated with these targeted therapies puts the cancer survivors at higher risk. Ponatinib is a third-generation TKI for the treatment of CML patients having gatekeeper mutation T315I, which is resistant to the first and second generation of TKIs, namely, imatinib, nilotinib, dasatinib, and bosutinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2020.05.077DOI Listing

Hypoxia: Turning vessels into vassals of cancer immunotolerance.

Cancer Lett 2020 May 26. Epub 2020 May 26.

UCD School of Medicine and UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, D04 C7X2, Ireland. Electronic address:

Hypoxia is a universal feature of solid cancers caused by a mismatch between cellular oxygen supply and consumption. To meet the increased demand for oxygen, hypoxic cancer cells (CCs) induce a multifaceted process known as angiogenesis, wherein new vessels are formed by the sprouting of pre-existing ones. In addition to providing oxygen for growth and an exit route for dissemination, angiogenic vessels and factors are co-opted by CCs to enable the generation of an immunotolerant, hypoxic tumor microenvironment, leading to therapeutic failure and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2020.05.015DOI Listing

Molecular imaging in lymphoma beyond F-FDG-PET: understanding the biology and its implications for diagnostics and therapy.

Lancet Haematol 2020 Jun;7(6):e479-e489

Department of Haematology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Electronic address:

Mature lymphoproliferative diseases are a heterogeneous group of neoplasms arising from different stages of B-cell and T-cell development. With improved understanding of the molecular processes in lymphoma and novel treatment options, arises a growing need for the molecular characterisation of tumours. Molecular imaging with single-photon-emission CT and PET using specific radionuclide tracers can provide whole-body information to investigate cancer biology, to evaluate phenotypic heterogeneity, to identify resistance to targeted therapy, and to assess the biodistribution of drugs in patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30065-XDOI Listing

Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.

Thorac Cancer 2020 May 29. Epub 2020 May 29.

University of Virginia / Riverside, Radiosurgery Center, Newport News, Virginia, USA.

Background: This study reports the outcomes of a single institutional experience treating non-small cell lung cancer (NSCLC) involving the pulmonary hilum with low-dose stereotactic body radiation therapy (SBRT). The authors also present a series of repeat hilar SBRT.

Methods: Inclusion criteria required treatment with SBRT for NSCLC involving regional lymph nodes of the: (i) hilum, (ii) mediastinum, (iii) aortopulmonary window (station 5), or (iv) mainstem bronchus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13501DOI Listing

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.

JAMA Oncol 2020 May 29. Epub 2020 May 29.

Dana-Farber Cancer Institute, Boston, Massachusetts.

Importance: Several immune checkpoint inhibitors (ICIs) are approved for use in patients with metastatic renal cell carcinoma (mRCC), but the efficacy and safety of ICI rechallenge in mRCC is unknown.

Objective: To evaluate the safety and efficacy of ICI rechallenge in patients with mRCC.

Design, Setting, And Participants: This multicenter, retrospective cohort study included consecutive patients with mRCC from 9 institutions in the US who received at least 2 separate lines of ICI (ICI-1, ICI-2) between January 2012 and December 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.2169DOI Listing

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.

JAMA Oncol 2020 May 29. Epub 2020 May 29.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Importance: Papillary renal cell carcinoma (PRCC) is the most common type of non-clear cell RCC. Because some cases of PRCC are MET-driven, MET inhibition could be a targeted treatment approach. In previous studies, savolitinib (AZD6094, HMPL-504, volitinib), a highly selective MET-tyrosine kinase inhibitor, demonstrated antitumor activity in this patient group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.2218DOI Listing

The mannose 6-phosphate receptor targeted with porphyrin-based periodic mesoporous organosilica nanoparticles for rhabdomyosarcoma theranostics.

Biomater Sci 2020 May 29. Epub 2020 May 29.

IBMM, UMR 5247 CNRS, UM-Faculté de Pharmacie, Avenue Charles Flahault, 34093, Montpellier Cedex 05, France.

Porphyrin-based periodic mesoporous organosilica nanoparticles (PMO) synthesized from a large functional octatriethoxysilylated porphyrin precursor and allowing two-photon excitation photodynamic therapy (TPE-PDT) and NIR imaging were synthesized. These PMO were grafted with polyethylene glycol (PEG) moieties and an analogue of mannose 6-phosphate functionalized at the anomeric position (AMFA). AMFAs are known to efficiently target mannose 6-phosphate receptors (M6PRs) which are over-expressed in various cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/d0bm00586jDOI Listing

Drugena: A Fully Automated Immunoinformatics Platform for the Design of Antibody-Drug Conjugates Against Neurodegenerative Diseases.

Adv Exp Med Biol 2020 ;1194:203-215

Genetics and Computational Biology Group, Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece.

Antibodies are proteins that are the first line of defense in the adaptive immune response of vertebrates. Thereby, they are involved in a multitude of biochemical mechanisms and clinical manifestations with significant medical interest, such as autoimmunity, the regulation of infection, and cancer. An emerging field in antibody science that is of huge medicinal interest is the development of novel antibody-interacting drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-32622-7_18DOI Listing
January 2020

Veratramine suppresses human HepG2 liver cancer cell growth in vitro and in vivo by inducing autophagic cell death.

Oncol Rep 2020 May 25. Epub 2020 May 25.

Department of Oncology, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China.

Liver cancer is the second leading cause of cancer‑related deaths. Traditional therapeutic strategies, such as chemotherapy, targeted therapy and interventional therapy, are inefficient and are accompanied by severe side effects for patients with advanced liver cancer. Therefore, it is crucial to develop a safer more effective drug to treat liver cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2020.7622DOI Listing

Identification of prognostic biomarkers and drug target prediction for colon cancer according to a competitive endogenous RNA network.

Mol Med Rep 2020 May 22. Epub 2020 May 22.

Department of Clinical Laboratory, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Chongming Branch, Shanghai 202150, P.R. China.

Colorectal cancer is one of the commoner digestive tract malignant tumor types, and its incidence and mortality rate are high. Accumulating evidence indicates that long‑chain non‑coding RNAs (lncRNAs) and protein‑coding RNAs interact with each other by competing with the same micro(mi)RNA response element (MREs) and serve an important role in the regulation of gene expression in a variety of tumor types. However, the regulatory mechanism and prognostic role of lncRNA‑mediated competing endogenous (ce)RNA networks in colon cancer have yet to be elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2020.11171DOI Listing

Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage.

Exp Mol Med 2020 May 28. Epub 2020 May 28.

Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, 139-706, Korea.

Endothelial-to-mesenchymal transition (EndMT) involves the phenotypic conversion of endothelial-to-mesenchymal cells, and was first discovered in association with embryonic heart development. EndMT can regulate various processes, such as tissue fibrosis and cancer. Recent findings have shown that EndMT is related to resistance to cancer therapy, such as chemotherapy, antiangiogenic therapy, and radiation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s12276-020-0439-4DOI Listing

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.

Melanoma Res 2020 May 27. Epub 2020 May 27.

Department of Oncology and Pathology, Karolinska Institutet, Bioclinicum, Solna.

Introduction of targeted therapy in the treatment of metastatic cutaneous malignant melanoma (CMM) has improved clinical outcome during the last years. However, only in a subset of the CMM patients, this will lead to long-term effects. CEBPB is a transcription factor that has been implicated in various physiological and pathological processes, including cancer development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000675DOI Listing

Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC.

Clin Genitourin Cancer 2020 Mar 6. Epub 2020 Mar 6.

Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.

Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment of metastatic clear cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) risk.

Patients And Methods: Treatment-naive patients with mCC-RCC were randomized to receive open-label sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU). The primary endpoint was first-line progression-free survival (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.01.001DOI Listing

Genetic profiling of patients with adenoid cystic carcinoma of the Bartholin's glands reveals potential new routes for targeted therapies: a case report.

Diagn Pathol 2020 May 28;15(1):64. Epub 2020 May 28.

Genomics Unit, Keio Cancer Center, Keio University School of Medicine, 35 Shinanomachi, Shinjukuku, Tokyo, 160-8582, Japan.

Background: Bartholin gland carcinomas (BGCs) are rare tumor types, for which no molecular analyses including genomic sequencing have been reported to date. Adenoid cystic carcinomas (ACCs) of the Bartholin's glands are an atypical histological type of BGC, and currently nothing is known regarding their genetic profiles or similarity to ACC carcinogenesis in other organs including the salivary glands, thereby limiting possible therapeutic options using precision medicine.

Case Presentation: We used targeted gene sequencing to analyze the occurrence of 160 cancer-related genes in two patients with BG-ACC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-020-00976-2DOI Listing

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy.

Cancers (Basel) 2020 May 26;12(6). Epub 2020 May 26.

Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 USA.

Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation in the past two decades as a promising molecular target for prostate cancer (PCa). Its appealing molecular features have enabled the development of a novel diagnostic and therapeutic-thus "theranostic"-approach to PCa. There is now substantial evidence of the high sensitivity of PSMA-targeted imaging for PCa lesions and growing evidence of the therapeutic efficacy of PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061367DOI Listing

Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.

Cancers (Basel) 2020 May 26;12(6). Epub 2020 May 26.

Université Côte d'Azur, INSERM, C3M, 06204 Nice, France.

Current treatments for metastatic cutaneous melanoma include immunotherapies and drugs targeting key molecules of the mitogen-activated protein kinase (MAPK) pathway, which is often activated by driver mutations. Overall responses from patients with metastatic mutant melanoma are better with therapies combining BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors. However, most patients that initially respond to therapies develop drug resistance within months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061364DOI Listing

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).

Cancers (Basel) 2020 May 26;12(6). Epub 2020 May 26.

Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA.

The advancement of new therapies, including targeted therapies and immunotherapies, has improved the survival of non-small-cell lung cancer (NSCLC) patients in the last decade. Some NSCLC patients still do not benefit from therapies or encounter progressive disease during the course of treatment because they have intrinsic resistance, acquired resistance, or lack a targetable driver mutation. More investigations on the molecular biology of NSCLC are needed to find useful biomarkers for current therapies and to develop novel therapeutic strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061361DOI Listing

Heterogeneity of Metabolic Vulnerability in Imatinib -Resistant Gastrointestinal Stromal Tumor.

Cells 2020 May 26;9(6). Epub 2020 May 26.

Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6:20, Karolinska University Hospital, SE-17164 Solna, Sweden.

Metabolic reprogramming is a hallmark of cancer cells in response to targeted therapy. Decreased glycolytic activity with enhanced mitochondrial respiration secondary to imatinib has been shown in imatinib-sensitive gastrointestional stromal tumors (GIST). However, the role of energy metabolism in imatinib-resistant GIST remains poorly characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9061333DOI Listing

Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies.

Cells 2020 May 26;9(6). Epub 2020 May 26.

Department of Biochemistry, College of Medicine, Chang-Gung University, Taoyuan 333, Taiwan.

Hepatocellular carcinoma (HCC) is a significant cause of cancer-related mortality owing to resistance to traditional treatments and tumor recurrence after therapy, which leads to poor therapeutic outcomes. Cancer stem cells (CSC) are a small subset of tumor cells with the capability to influence self-renewal, differentiation, and tumorigenesis. A number of surface markers for liver cancer stem cell (LCSC) subpopulations (EpCAM, CD133, CD44, CD13, CD90, OV-6, CD47, and side populations) in HCC have been identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9061331DOI Listing